The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.82
Bid: 3.70
Ask: 3.94
Change: 0.01 (0.26%)
Spread: 0.24 (6.486%)
Open: 3.81
High: 0.00
Low: 0.00
Prev. Close: 3.81
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

29 Jan 2016 07:00

RNS Number : 3769N
Plant Health Care PLC
29 January 2016
 

 

 

PLANT HEALTH CARE plc

 

("Plant Health Care" or the "Company")

 

 

Trading Update

 

Plant Health Care, a leading provider of novel patent-protected biological products to the global agriculture markets, issues the following post year-end trading update ahead of the announcement of the Company's audited full year financial results for the year ended 31st December 2015, which is expected no later than the first week of April. All results provided are preliminary and subject to completion of the 2015 audit.

 

The Company is pleased to report strong financial performance in FY2015 in line with expectations. Progress with our Plant Response Elicitor technology ("PREtec") platform has accelerated.

 

Financial and Commercial Highlights

- Revenue of approximately $7.5m; growth year over year at constant currency was 15%; 9% growth in US$, largely due to the weakness of the Mexican peso

- Sales of the core Harpin products increased by 22%, driven by strong sales in the United States and Europe; Harpin and Myconate® products represented 57% of sales in 2015 (2014: 53%)

- Gross Margin increased to 62% in 2015 from 51% in 2014

- Cash and cash equivalents at 31st December 2015 were $8.4m

- Revenue growth in Mexico of approximately 14% in local currency

- In conjunction with a significant increase in R&D investment to $5.7m in 2015, the overall operating result was a loss of approximately $7.3m in 2015 as compared to $6.1m in 2014

- A roughly two-fold increase in sales to Sym-Agro, a key partner in the Pacific North West

- Achieved the Company's first product registration in Brazil; now preparing for a launch in sugar cane

 

PREtec Highlights

- Signed four evaluation agreements with major players in the agriculture industry for our first family of PREtec peptides, Innatus 3G

- Completed third year of field trials in corn with Innatus 3G, including one peptide variant with three years of field trial data delivering an average yield increase of 9.6 bushels per acre when applied as a seed treatment compared with industry standard treatments alone, with a win rate of 79%, with data from 19 of 20 sites analyzed to date

- Very promising early results on additional peptide families beyond Innatus 3G

- Significantly strengthened the R&D team in Seattle and our licensing capability; moved into expanded laboratories in 3Q

 

Paul Schmidt, CEO, commented:

"2015 was a pivotal year for Plant Health Care. We made substantial progress in growing our commercial business and advancing our PREtec platform.

We are engaging actively with our evaluation partners for Innatus 3G, our first PREtec peptide family, and are encouraged by positive early results. Field and laboratory trials continue and are anticipated to further reinforce the initial promise of this family.

 

Our expanded research team in Seattle is making rapid strides, and we are very encouraged by the early results of studies on other peptide families beyond Innatus 3G. We intend to continue to evaluate and advance these additional peptide families and anticipate presenting at least one new family to potential partners during 2016.

On the commercial side, sales of Harpin αβ continued to grow; we have recorded 22% CAGR from 2012 to 2015, excluding license payments. This is despite strong headwinds in the agriculture industry due to low commodity prices. Increased demand for both Harpin αβ and Myconate in specialty crops has led to strong sales growth in our Mexico subsidiary as well as via Sym-Agro in the Pacific North West. In Brazil, our partner is conducting a further year of trials in sugar cane, prior to its anticipated launch of Harpin αβ.

 

This is an exciting time for Plant Health Care. We are advancing in line with our strategy and confident in our future direction."

 

 

For further information, please contact:

 

Plant Health Care plc

Paul Schmidt, Chief Executive Officer Tel: +1 919 926 1600

Jeffrey Hovey, Chief Financial Officer

 

Liberum Capital - Nomad and Broker

Clayton Bush / Chris Clarke Tel: +44 (0) 20 3100 2000

 

LHA

Ed McGregor / Jody Burfening Tel: +1 (212) 838 3777

 

Company website: www.planthealthcare.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTLFFVILSITFIR
Date   Source Headline
18th Aug 20214:36 pmRNSPrice Monitoring Extension
9th Aug 20211:27 pmRNSHolding(s) in Company
3rd Aug 20217:00 amRNSAdmission to the U.S. OTCQB Venture Market
27th Jul 20217:00 amRNSNew Distribution Agreement with Agrii UK
26th Jul 20217:00 amRNS2021 Half-Year Trading Statement
23rd Jul 20217:00 amRNSGrant of Options
22nd Jul 20217:00 amRNSInvestor Presentation
12th Jul 20214:40 pmRNSSecond Price Monitoring Extn
12th Jul 20214:35 pmRNSPrice Monitoring Extension
29th Jun 20214:41 pmRNSSecond Price Monitoring Extn
29th Jun 20214:35 pmRNSPrice Monitoring Extension
14th Jun 20212:33 pmRNSResult of AGM
14th Jun 20217:00 amRNSGreen Economy Mark awarded
9th Jun 20214:41 pmRNSSecond Price Monitoring Extn
9th Jun 20214:35 pmRNSPrice Monitoring Extension
20th May 20217:00 amRNSInvestor Presentation
7th May 20213:50 pmRNSAnnual Report & Accounts and AGM Notice Published
30th Apr 20215:40 pmRNSHolding(s) in Company
23rd Apr 20217:00 amRNSResults for the year ended 31 December 2020
21st Apr 202111:58 amRNSHolding(s) in Company
8th Apr 20213:30 pmRNSHolding(s) in Company
1st Apr 20217:00 amRNSTotal Voting Rights
22nd Mar 20217:00 amRNSInvestor Presentation
18th Mar 20211:57 pmRNSResults of Placing and Subscription
18th Mar 20217:00 amRNSProposed Placing and Subscription
1st Mar 20217:00 amRNSSaori Trial Update
3rd Feb 20214:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20214:36 pmRNSPrice Monitoring Extension
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:36 pmRNSPrice Monitoring Extension
25th Jan 20217:00 amRNSTrading Statement
11th Jan 20217:00 amRNSNotice of Trading Statement/Investor Presentation
5th Jan 20213:37 pmRNSBrazil approves PHC279 to Control Soybean Rust
11th Dec 20207:00 amRNSInvestor Presentation
9th Nov 20207:00 amRNSPlant Health Care and Wilbur-Ellis sign Agreement
7th Oct 20207:00 amRNSGrant of Options
6th Oct 20207:00 amRNSNew US PREtec Patents Issued
2nd Oct 20205:48 pmRNSSignificant Shareholder
25th Sep 20207:00 amRNSInvestor Presentation
23rd Sep 20207:00 amRNSInvestor Presentation
15th Sep 20207:00 amRNSInterim Report 30 June 2020
29th Jul 20207:00 amRNSTrading Statement
26th Jun 20204:41 pmRNSSecond Price Monitoring Extn
26th Jun 20204:36 pmRNSPrice Monitoring Extension
25th Jun 20207:00 amRNSGrant of Options
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSPHC398 Approved by US EPA: PHC279 submitted to EPA
9th Jun 20207:00 amRNSGrant of options
2nd Jun 202011:13 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.